ResMed Ownership
| RMD Stock | USD 261.63 3.71 1.44% |
Shares in Circulation | First Issued 1992-09-30 | Previous Quarter 147.6 M | Current Value 147.2 M | Avarage Shares Outstanding 132.9 M | Quarterly Volatility 27.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. ResMed Stock Ownership Analysis
About 65.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.53. ResMed Inc recorded earning per share (EPS) of 8.9. The entity last dividend was issued on the 8th of May 2025. The firm had 2:1 split on the 31st of August 2010. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 8160 people. To find out more about ResMed Inc contact BE MBA at 858-836-5000 or learn more at https://www.resmed.co.in.Besides selling stocks to institutional investors, ResMed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ResMed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ResMed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ResMed Quarterly Liabilities And Stockholders Equity |
|
ResMed Insider Trades History
Less than 1% of ResMed Inc are currently held by insiders. Unlike ResMed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ResMed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ResMed's insider trades
ResMed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ResMed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ResMed Inc backward and forwards among themselves. ResMed's institutional investor refers to the entity that pools money to purchase ResMed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2025-03-31 | 955.3 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 793.8 K | Los Angeles Capital Management Llc | 2025-03-31 | 773.2 K | Barclays Plc | 2025-03-31 | 740.4 K | Goldman Sachs Group Inc | 2025-03-31 | 739 K | Nordea Investment Mgmt Bank Demark A/s | 2025-03-31 | 732.2 K | Amundi | 2025-03-31 | 631.1 K | Ubs Group Ag | 2025-03-31 | 621.5 K | Jpmorgan Chase & Co | 2025-03-31 | 568.8 K | Vanguard Group Inc | 2025-03-31 | 18.5 M | Blackrock Inc | 2025-03-31 | 12.7 M |
ResMed Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ResMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on ResMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ResMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ResMed's latest congressional trading
Congressional trading in companies like ResMed Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in ResMed by those in governmental positions are based on the same information available to the general public.
| 2025-06-19 | Representative Kelly Louise Morrison | Acquired Under $15K | Verify | ||
| 2025-05-14 | Representative Kelly Louise Morrison | Acquired Under $15K | Verify | ||
| 2024-06-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-09-04 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2023-02-02 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2023-02-01 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2022-11-09 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
ResMed Outstanding Bonds
ResMed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ResMed Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ResMed bonds can be classified according to their maturity, which is the date when ResMed Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US76119LAB71 Corp BondUS76119LAB71 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
ResMed Corporate Filings
F4 | 9th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 29th of May 2025 Other Reports | ViewVerify | |
8K | 23rd of April 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of March 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.216 | Dividend Share 2.07 | Earnings Share 8.9 | Revenue Per Share | Quarterly Revenue Growth 0.079 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.